4.7 Review

Multiple sclerosis: risk factors, prodromes, and potential causal pathways

期刊

LANCET NEUROLOGY
卷 9, 期 7, 页码 727-739

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/S1474-4422(10)70094-6

关键词

-

资金

  1. Bayer-Schering Healthcare
  2. Biogen-Idec
  3. GlaxoSmithKline
  4. Merck-Serono
  5. Novartis
  6. Protein Discovery Laboratories
  7. Teva-Aventis
  8. UCB Pharma
  9. Biogen Idec
  10. Merz
  11. MRC
  12. National MS Society
  13. MS Society of Great Britain and Northern Ireland
  14. AIMS2CURE
  15. Roan Charitable Trust
  16. Guarantors of Brain
  17. MRC [G0801975] Funding Source: UKRI
  18. Medical Research Council [G0801975] Funding Source: researchfish

向作者/读者索取更多资源

Multiple sclerosis (MS) is a common, complex neurological disease. The precise aetiology of MS is not yet known, although epidemiological data indicate that both genetic and environmental factors are important. The evidence that the environment acts long before MS becomes clinically evident is well established and suggests the existence of a prodromal phase for the disease. The increasing incidence of MS emphasises the need for strategies to prevent this chronic disorder, and the possibility of a prodrome indicates a window of opportunity to potentially reverse early disease processes before clinical disease becomes evident. Studying a prodrome requires techniques other than clinical observation such as monitoring endophenotypes that result from associated risk factors. However, our current knowledge of causal pathways and endophenotypes in MS is limited. Identifying and studying individuals with a high risk of developing the disease provides a powerful opportunity to understand the MS causal cascade and is highly relevant to strategies that are aimed at preventing this debilitating disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据